Business Wire

UK High Court Victory for Koza Altin in Ipek litigation


The High Court in London has delivered another blow to businessman Hamdi Akin Ipek, granting an injunction preventing him from using funds belonging to Koza Ltd, the English subsidiary of a publicly-listed Turkish mining conglomerate. Mr Ipek wanted to use millions of Koza Ltd's funds to pay for a personal international arbitration dispute between him and the Republic of Turkey.

Following a 2-day hearing in the High Court in London on 10 and 11 February 2020, Mr Jeremy Cousins QC (a Deputy Judge of the High Court) ruled on Monday that Koza Ltd's funds should not be used in support of the arbitration – in particular since it appeared the arbitration was being pursued based on a document of doubtful authenticity.

Mr Ipek had claimed he could not pay for the arbitration personally, and that without Koza Ltd's funds it could not go ahead. At the court hearing, however, Koza Altin submitted evidence showing that Mr Ipek and his family members had been "shuffling" more than $20million between them and dealing in luxury yachts. The Court heard that Mr Ipek must have access to sufficient funds of his own to pay for the arbitration. The judge was unimpressed by Mr Ipek’s failure to disclose his assets, deciding that "Mr Ipek's position remains shrouded with an uncertainty that Mr Ipek has done nothing to dispel" and that his refusal to cooperate to enable proper scrutiny of his asset position was "extremely unimpressive and unsatisfactory."

This week’s ruling means that Koza Ltd’s funds are preserved pending trial.

Hugo Plowman, the Partner at Mishcon de Reya LLP representing Koza Altin, commented:

"This is an important decision and a clear message from the English Court that Mr Ipek must stop using Koza Ltd’s funds to fight his campaign against Turkey. My client is delighted with this result which follows our major win in the Supreme Court last summer."

The decision is the latest in a series of defeats suffered by Mr Ipek in ongoing litigation over control of Koza Ltd.

Koza Ltd is the wholly-owned English subsidiary of Koza Altin, a publicly-listed mining conglomerate headquartered in Ankara. Koza Ltd was incorporated in 2014 and capitalised with £60million provided by its parent company, Koza Altin.

Over the course of the past 4 years, Koza Altin has taken action to stop these funds being used inappropriately. In 2016, the funds were frozen in order to preserve the value of the company pending resolution of the dispute. In 2017, Mr Ipek sought the Court's permission to release Koza Ltd’s funds to finance a raft of personal litigation, including £3million for an international arbitration claim that he planned to bring against Turkey on behalf of another company owned by him and his family called Ipek Investments Limited. Koza Altin contested his application, arguing that this was an inappropriate use of assets ultimately held for the benefit of Koza Altin’s shareholders. Koza Altin also argued that the arbitration was founded upon a fraudulent share purchase agreement (the SPA) and, since it was a sham, the Court should not sanction use of frozen funds to pursue the arbitration.

On that occasion, Richard Spearman QC (a Deputy Judge of the High Court) decided that the authenticity of the SPA underpinning Mr Ipek's right to bring the arbitration was "open to very serious doubt". This was upheld on appeal in 2019 when the Court of Appeal concluded that Mr Spearman was "plainly correct" in his assessment of the authenticity of the document and that "once there is accepted to be a seriously arguable case that the SPA was a forgery… the court plainly should not lend its authority to a transaction when there is a real possibility that the transaction is a fraudulent one".

In his judgment this week, Mr Cousins QC agreed with the earlier rulings. He confirmed that there "remain reasons for very serious doubt as to the SPA’s authenticity." This, he said, is "highly material" to Mr Ipek’s prospects of success in the arbitration.

Last summer, another issue was settled in Koza Altin’s favour when the Supreme Court dismissed Mr Ipek’s claims challenging the authority of directors appointed by the Turkish Court to represent Koza Altin. The decision represented the culmination of almost three years of litigation on jurisdiction.

What is left of the claim can now proceed to trial in England where the Court will decide who should be able to control Koza Ltd. Koza Altin maintains that Mr Ipek is improperly and unlawfully seeking to prevent it from exercising its rights as the 100% shareholder of Koza Ltd. Koza Altin is seeking the removal of Mr Ipek as a director of Koza Ltd in order to protect Koza Altin and its assets for the benefit of its shareholders, and in accordance with its regulatory obligations.


Contact information

Media enquiries:
Conal Walsh / Jack Myers
+44 (0)7912 515089

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

British Firm BitePRO Claim Mental Health Care Professionals Are At Risk Of Being Bitten26.2.2020 17:12:00 CETPress release

According to British firm BitePRO, mental health care and special educational needs professionals are at increased risk of being bitten by patients or pupils. This press release features multimedia. View the full release here: Healthcare nurse wearing BitePRO® Bite Resistant Clothing (Photo: Business Wire) Many nurses, care workers and teachers retire on medical grounds. They walk away from the profession they were once extremely passionate about, partly because medical experts have been able to identify that they suffer from real trauma and severe stress. Others, like Minnesota based Special Education Assistant Erin Gonzales are keen to continue and state: “I work at a school where human bites are a daily occurrence, but I work with kids with special needs. But honestly, I wouldn’t trade it for the world.” Oklahoma based Psychiatric Nurse Practitioner Miranda Hagan shares her desire and refuses to give up: “I have permanent sca

BIOCORP: Marketing Partnership on Mallya with iSage Rx in the Field of Digital Diabetes19.2.2020 17:00:00 CETPress release

Regulatory News: BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, today announced an alliance with US-based iSage Rx, LLC., a digital therapeutics company, focused on insulin dose optimization. In detail, the two companies are committed to integrating their respective technologies to simplify insulin dose capture and optimization. The integration of Mallya (a CE-marked connected device dedicated to insulin pens) into the iSage app (a clinically validated insulin titration platform cleared by the FDA) should enable patients with type 2 diabetes to simplify their insulin management. This will allow patients with diabetes to seamlessly capture, record, and store information about their insulin injections and while receiving automated guidance on how to adjust their insulin dose overtime ("titration"). Ryan Sysko, President and CEO of Amalgam Rx, Inc, said:

New Phase 3b Interim Data from STARDUST Study Show Two-Thirds of Patients with Moderately to Severely Active Crohn’s Disease Achieved Clinical Remission After Two Doses of STELARA® (ustekinumab)14.2.2020 07:00:00 CETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced interim data from the Phase 3b STARDUST study. At week 16, 79 percent of patients with moderately to severely active Crohn’s disease (CD) achieved clinical responsea and 67 percent were in clinical remissionb after receiving one ~6 mg/kg intravenous (IV) dose followed by one 90 mg subcutaneous (SC) dose of STELARA® (ustekinumab), open label.1 Intestinal ultrasound (IUS) responses were assessed and were detected as early as week 4.2 Week 16 data (digital oral presentation or DOP 13) and IUS response data (DOP 10) from STARDUST are being presented as part of a digital oral presentation at the 15th Congress of the European Crohn’s & Colitis Organisation (ECCO).1,2 The primary endpoint of the 48-week STARDUST study is comparative endoscopic responsec among adult patients with CD receiving ustekinumab maintenance therapy.3 At week 16, patients who achieved a ≥70 point decrease in Crohn’s Disease Activity Index scored

Edwards Launches New Compact Dry Vacuum Pump With the Highest Pumping Density on the Market13.2.2020 13:07:00 CETPress release

Edwards launch the new nXRi high performance compact dry pump, with lower input power and zero maintenance, bringing real performance improvements and cost benefits across a range of applications. Initial variants will provide pumping speeds of either 60 and 90 m3h-1 , four times more pumping speed than a similar sized dry pump. This press release features multimedia. View the full release here: Edward nXRi Compact Dry Vacuum Pump (Photo: Business Wire) Designed with size in mind, the compact footprint and height allow the Edwards nXRi dry pump to fit easily under a benchtop saving valuable space in the laboratory; and at under 30kg offers a highly mobile vacuum pump for changing work flows and environments. The pump is maintenance free for up to five years, with no tip-seal or oil change, for maximum uptime and reduced maintenance costs. The nXRi's 40% smaller footprint, compared to alternative dry pumps, assures seamless integ

Interactive Brokers Launches Bond Scanner to Help Investors Find the Best Pricing on Wide Range of Fixed Income Products12.2.2020 15:00:00 CETPress release

Interactive Brokers Group, Inc. (Nasdaq: IBKR) today announced it has created a Bond Scanner to help make finding the best prices on bonds easier and more transparent for clients and non-clients alike. “We believe we offer the lowest bond prices available. Investors should visit our Bond Scanner at, filter for bonds of interest, and then call their broker to compare,” said Steven Sanders, EVP of Marketing and Product Development at Interactive Brokers. “Clients benefit from our aggregation of price quotes from multiple electronic venues and institutional dealers,” he added. “We do not widen spreads nor are there hidden fees or markups. While some companies charge a large, hidden markup, we charge extremely low, transparent commissions. IBKR clients may provide liquidity to bond markets and improve pricing by entering their own pending orders into the book.” In addition to ultra-low, transparent pricing, the company offers a huge selection of fixed income products, includ

ADVA tackles GNSS jamming and spoofing with market’s first intelligent assurance solution11.2.2020 08:00:00 CETPress release

ADVA (FSE: ADV) today launched the industry’s first centralized GNSS monitoring and assurance tool. Using artificial intelligence (AI) and machine learning (ML) for comprehensive predictive maintenance, it addresses the key concerns of GNSS users around the globe. The new customer-owned tool enables users to collect and analyze huge amounts of information from across the network to remotely identify issues and protect networks from GNSS vulnerabilities, including jamming and spoofing attacks. It also helps to identify GNSS obstruction issues, detect blind/poor spots that appear over time and enable optimal antenna positioning. Built into ADVA’s Ensemble Controller network management suite with Sync Director, the solution enables customers to detect potential problems in advance, maintain the highest quality of network synchronization and significantly reduce opex. By complementing today’s limited distributed approach to GNSS assurance with a centralized-global system, it offers a major